Xeris Biopharma【0A8E】銘柄情報

Xeris Biopharma Holdings Inc (0A8E) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

( - )

買値

0.00

売値

0.00

出来高

1,404

平均取引量 (3 か月)

US$ 1,776,755

財務取引量

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

企業価値

1.576B

前日終値

0.00

始値

時刻

8.58

(O)

最終取引時間

VWAP

歳入

314.85M

純利益

12.01M

発行済株式数

172,642,055

浮動株比率 (%)

96.55%

機関投資家保有比率 (%)

62.30%

配当利回り

PER

129.17

株価売上高倍率 (PSR)

4.54

1 株当たり利益 (EPS)

0.06

ベータ

0.85

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric ... Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. 詳細を表示

セクター

業界

ウェブサイト

www.xerispharma.com

本社

Chicago, United States

設立

2026

Xeris Biopharma Holdings Inc is listed in the sector of the ロンドン証券取引所 with ticker 0A8E. The last closing price for Xeris Biopharma was US$0. Over the last year, Xeris Biopharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Xeris Biopharma currently has 172,642,055 shares in issue. Xeris Biopharma has a price to earnings ratio (PE ratio) of 129.17.